Publikationen, an denen er mitarbeitet Juan Fabregat (7)

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients

    Clinical Transplantation, Vol. 29, Núm. 8, pp. 667-677

2011

  1. A prospective, multicenter study of once-daily extended-release tacrolimus in de novo liver transplant recipients

    Transplantation Proceedings

2008

  1. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: Results of a prospective randomized study

    Liver Transplantation, Vol. 14, Núm. 12, pp. 1752-1760

2006

  1. Corrigendum to "Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study" [J Hepatol 44 (2006) 710-716] (DOI:10.1016/j.jhep.2005.12.010)

    Journal of Hepatology

  2. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study

    Journal of Hepatology, Vol. 44, Núm. 4, pp. 710-716